What’s next for Europe’s best performing stock, up 1,400%
Key Points Abivax shares are up more than 1,400% year to date as investors are optimistic about the prospects of its treatment for ulcerative colitis. “We are certainly excited about the work we are doing, and we’ve been greeted again by the medical community as becoming possibly this next standard of care in ulcerative colitis,”…